Elise Anderes, MD
Hematology & Oncology · Kalispell, MTNPI 1558535997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 34.0% of the total. Reporting peaked in 2019 at $319 and has fallen 94.7% since, to $17 in 2021. That places this record below the midpoint for hematology & oncology clinicians in MT, where the typical reported total is $507.
Across 31 payments — averaging $13.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$138
- Eisai Inc.$65
- Novartis$50
- Pharmacyclics LLC, An Abbvie Company$37
- Gilead$24
- Astellas Pharma US Inc$23
- plus $69 from 5 others
Across 111 payments — averaging $1254.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$86K
- Chiesi USA, Inc.$28K
- Janssen Research & Development, LLC$22K
- Bristol Myers Squibb$3K
- Merck$404
What the payments were for
- Food & beverage$38996%
- Education$174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 13 | $138 |
| Eisai Inc. | 4 | $65 |
| Novartis | 3 | $50 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $37 |
| Gilead(2 entities) | 2 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Merck | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$406 in reported general payments places this provider in the 45th percentile of 37 hematology & oncology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 18 | $280,008 |
| InqoviDecitabine/Cedazuridine | 13 | $105,255 |
| EliquisApixaban | 47 | $38,783 |
| ValacyclovirValacyclovir Hcl | 17 | $1,809 |
| Anastrozole | 82 | $1,449 |
| Ondansetron OdtOndansetron | 71 | $1,436 |
| Tamoxifen Citrate | 56 | $1,302 |
| Exemestane | 12 | $1,043 |
| Hydroxyurea | 37 | $829 |
| Dexamethasone | 39 | $626 |
| Prochlorperazine Maleate | 44 | $594 |
| Imatinib Mesylate | 12 | $521 |
| Gabapentin | 41 | $417 |
| Pantoprazole Sodium | 11 | $230 |
| Oxycodone Hcl | 15 | $225 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Kalispell
- Ryan RoopKalispell$2K
- Peter WagnerKalispell$2K
- Kyle KondratKalispell$379
- Karen HuntKalispell$125
- John WardKalispell$72
- Patrick CobbBillings$21K
- Thomas WeinerHelena$14K
- Aaron FrankeSidney$11K
- Carolyn AksHavre$9K
- Karl GuterGreat Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.